Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America.

Next Previous
Trial Profile

Cost Effectiveness Of Linezolid Vs Vancomycin In The Treatment Of Ventilator Acquired Pneumonia In Central America.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Linezolid (Primary) ; Vancomycin
  • Indications Bacterial infections; Nosocomial pneumonia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 29 Jul 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 27 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Jul 2011 as reported by ClinicalTrials.gov.
  • 03 Jun 2011 Planned end date changed from May 2011 to Jun 2011 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top